Skip to main content
Top

15-02-2019 | Castration-resistant prostate cancer | News

ASCO GU 2019 in brief

Further support for [177Lu]-PSMA-617 in men with mCRPC

print
PRINT
insite
SEARCH

medwireNews: Results from an expansion cohort add support for the use of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-617 in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC).

Michael Hofman (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) and co-researchers previously demonstrated “favourable activity and toxicity” of the radionuclide agent in a phase II trial comprising 30 mCRPC patients who had progressed on standard therapy.

And now they report at the 2019 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA, findings from an additional 20 participants, which showed that treatment with a median four cycles of [177Lu]-PSMA-617 led to a decline in prostate-specific antigen (PSA) levels of at least 30% in 74% of the 50-patient cohort.

A PSA decline of at least 50% occurred in 64% of patients, while 44% had a PSA decline of 80% or more during a median follow-up of 23.5 months.

Overall survival was a median of 13.3 months for the whole cohort, and was 33 months for the 14 men who were rechallenged with [177Lu]-PSMA-617 after initial progression. Nearly two-thirds (64%) of these patients achieved a PSA decline of 50% or more, reported the presenting author.

And Hofman concluded: “Despite multiple lines of prior therapies failing, the high response rates observed in these patients support a novel mechanism of action of 177Lu-PSMA-617 theranostics compared to existing therapies.”

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

print
PRINT